Protalix BioTherapeutics, Inc. (de) · AMEX:PLX
Protalix BioTherapeutics, Inc. (de) — Investor Presentation (August 2023)
13 slides from Protalix BioTherapeutics, Inc. (de)'s investor presentation, August 2023
Slide 1: Protalix Biotherapeutics Corporate Presentation August 2023
PROTALIX BIOTHERAPEUTICS CORPORATE PRESENTATION August 2023
Slide 2: Disclaimers
Disclaimers Third-Party Information This presentation also contains estimates and other data made by independent parties and Protalix relating to market size and growth and other data related to the industry in which Protalix operates. This data involves a number of assumptions and limitations, and
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Exchange Act. Forward-looking statements are neither histor
Slide 4: Investment Highlights
Investment Highlights A Strong Foundation To Further Expand Into The Rare Disease Space Two Approved Drugs in LSDs Clinical and Regulatory Expertise in Rare Elelyso® (alfataliglicerase in Brazil): FDA approved, commercially marketed Genetic Space drug for Gaucher disease. Strong clinical and regulat
Slide 5: Product Pipeline
Product Pipeline Recombinant proteins designed to have potentially improved therapeutic profiles that target unmet medical needs and established pharmaceutical markets Discovery and Preclinical Phase I Phase II Phase III Marketing Application Elelyso® Gaucher Disease Approved in 23 markets (taligluc
Slide 6: Elelyso for Gaucher Disease
Elelyso® for Gaucher Disease First plant cell derived recombinant protein approved by the FDA Gaucher Disease Symptoms and Treatment • Rare autosomal recessive disorder: affects 1 in • Possible symptoms include enlarged liver and 40,000 people spleen, various bone disorders, easy bruising and • Gluc
Slide 7: Elfabrio for Fabry Disease
Elfabrio® for Fabry Disease Second plant cell derived recombinant protein approved by the FDA Fabry Disease Symptoms and Treatment • Progressive disease that can lead to renal failure, • Rare X-linked disease: affecting about one in every cardiomyopathy with potentially malignant cardiac 40,000 to 6
Slide 8: Committed Commercial Partner Chiesi Farmaceutici S.p.A.
Committed Commercial Partner Global Partnership with Chiesi Farmaceutici S.p.A. • International research-focused • Committed global partner with pharmaceuticals and healthcare group with ~$3B in revenue experienced sales team • Operating in 30 countries with over 6,000 • Strategic focus on Rare Dise
Slide 9: Growing Focus on High Unmet Needs in Rare Disease Space
Growing Focus on High Unmet Needs in Rare Disease Space Focus on Rare Disease Space Our Strategy: Focus on rare diseases space Goal: Within 2 years, 4-6 discovery to PhII programs in the pipeline • Both genetic and non-genetic opportunities • Prioritize opportunities with LCM potential Rare Genetic
Slide 10: Evolving Protalix: Addressing High Unmet Needs in the Rare Disease Space
Evolving Protalix: Addressing High Unmet Needs in the Rare Disease Space Leveraging track record of success into other rare diseases Strategy Striving for Continued Success in Rare Diseases (genetic and non-genetic) Track Record of Success in Rare Genetic Space Vision Next Steps Protalix Now Initial
Slide 11: Well Capitalized to Advance Protalix to Next Phase
Well Capitalized to Advance Protalix to Next Phase CASH REVENUE $48.2M (2Q’23) $44.7M in revenue (H1 2023) FINANCING NET BURN RATE Successfully completed a Note Exchange Projected: 0 to +$1.5 M/Q in 3Q’21 to effectively extend maturity from 2021 to 2024 and lower principal CASH RUNWAY DEBT Cash Runw
Slide 12: Experienced Leadership Team
Experienced Leadership Team DROR BASHAN EINAT BRILL ALMON, PH.D. EYAL RUBIN YARON NAOS YAEL HAYON, PH.D. President & CEO Senior Advisor (former SVP, Chief SVP & CFO SVP of Operations VP of R&D Development Officer) Mr. Bashan has served as our Dr. Almon joined Protalix in Mr. Rubin has served as our
Slide 13: Accomplished Board of Directors
Accomplished Board of Directors ZEEV BRONFELD DROR BASHAN POL F. BOUDES, M.D. GWEN A. MELINCOFF Chairman President & CEO, Director Director Director AHARON SCHWARTZ, PH.D. AMOS BAR SHALEV SHMUEL “MULI” BEN ZVI, PH.D. Director Director Director Corporate Presentation I August 2023 13
Protalix BioTherapeutics — Investor Presentation (August 2023) on 6ix